EXEL EXELIXIS, INC.
Nasdaq · SEC CIK 939767 · EDGAR
- Bought, last 12 months
- $1.19M 1 purchases by 1 insiders
- Sold, last 12 months
- $42.24M 24 sales by 12 insiders
- Filings on record
- 313 since 2021-07-08, latest 2026-08-12 19:34
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Aftab Dana | EVP, Research, Development | — | $7.70M |
| Haley Patrick J. | EVP, Commercial | — | $7.60M |
| Smith Julie | Dir | — | $4.69M |
| WYSZOMIERSKI JACK L | Dir | — | $4.58M |
| Senner Christopher J. | EVP, CFO | — | $4.56M |
| PAPADOPOULOS STELIOS | Dir | — | $4.36M |
| POSTE GEORGE | Dir | — | $2.74M |
| Beckerle Mary C | Dir | — | $1.93M |
| Oliver Bob | Dir | — | $1.33M |
| Caligan Partners LP | Dir, See Remarks | $1.19M | — |
Transactions 443
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-17 | 2021-12-15 | EXEL | MORRISSEY MICHAEL | Pres, CEO, Dir | A - Grant | $0.00 | +46.5K | 217.2K | +27% | $0 | |
| 2021-12-17 | 2021-12-15 | EXEL | MORRISSEY MICHAEL | Pres, CEO, Dir | F - Tax | $17.00 | -12.2K | 205.0K | -6% | -$208.0K | |
| I | 2021-12-17 | 2021-11-29 | EXEL | MORRISSEY MICHAEL | Pres, CEO, Dir | G - Gift | $0.00 | +196.5K | 1.24M | +19% | $0 |
| D | 2021-12-17 | 2021-12-16 | EXEL | Wright Jacqueline | Dir | A - Grant | $0.00 | +20.9K | 20.9K | New | $0 |
| 2021-12-17 | 2021-12-15 | EXEL | Hessekiel Jeffrey | EVP, GC | A - Grant | $0.00 | +9,994 | 588.2K | +2% | $0 | |
| 2021-12-17 | 2021-12-15 | EXEL | Hessekiel Jeffrey | EVP, GC | F - Tax | $17.00 | -2,621 | 585.6K | -0.4% | -$44.6K | |
| 2021-11-26 | 2021-11-24 | EXEL | Haley Patrick J. | EVP, Commercial | S - Sale | $17.25 | -17.2K | 237.8K | -7% | -$297.3K | |
| D | 2021-11-23 | 2021-11-19 | EXEL | FELDBAUM CARL B | Dir | S - Sale+OE | $17.62 | -20.0K | 8,521 | -70% | -$352.4K |
| D | 2021-11-23 | 2021-11-19 | EXEL | FELDBAUM CARL B | Dir | M - OptEx | $3.13 | +20.0K | 28.5K | +235% | +$62.6K |
| D | 2021-11-17 | 2021-11-15 | EXEL | Lamb Peter | EVP, CSO, Scientific Strategy | S - Sale+OE | $18.09 | -47.5K | 411.2K | -10% | -$859.3K |
| DM | 2021-11-17 | 2021-11-15 | EXEL | Lamb Peter | EVP, CSO, Scientific Strategy | F - Tax | $18.10 | -62.2K | 404.4K | -13% | -$1.13M |
| D | 2021-11-17 | 2021-11-15 | EXEL | Lamb Peter | EVP, CSO, Scientific Strategy | M - OptEx | $6.21 | +47.5K | 458.7K | +12% | +$295.0K |
| M | 2021-11-17 | 2021-11-15 | EXEL | Hessekiel Jeffrey | EVP, GC | F - Tax | $18.10 | -54.6K | 578.2K | -9% | -$988.5K |
| M | 2021-11-17 | 2021-11-15 | EXEL | MORRISSEY MICHAEL | Pres, CEO, Dir | F - Tax | $18.10 | -193.8K | 550.5K | -26% | -$3.51M |
| M | 2021-11-17 | 2021-11-15 | EXEL | Haley Patrick J. | EVP, Commercial | F - Tax | $18.10 | -49.5K | 300.2K | -14% | -$895.8K |
| M | 2021-11-17 | 2021-11-15 | EXEL | Senner Christopher J. | EVP, CFO | F - Tax | $18.10 | -57.7K | 404.7K | -12% | -$1.04M |
| 2021-11-03 | 2021-11-01 | EXEL | Hessekiel Jeffrey | EVP, GC | S - Sale | $22.03 | -5,117 | 632.8K | -0.8% | -$112.7K | |
| 2021-10-22 | 2021-10-22 | EXEL | MORRISSEY MICHAEL | Pres, CEO, Dir | F - Tax | $21.33 | -24.7K | 561.1K | -4% | -$527.9K | |
| 2021-10-22 | 2021-10-22 | EXEL | MORRISSEY MICHAEL | Pres, CEO, Dir | A - Grant | $0.00 | +94.0K | 585.8K | +19% | $0 | |
| 2021-10-15 | 2021-10-15 | EXEL | Hessekiel Jeffrey | EVP, GC | S - Sale | $22.02 | -12.9K | 637.9K | -2% | -$283.7K | |
| D | 2021-10-15 | 2021-10-15 | EXEL | Lamb Peter | EVP, CSO, Scientific Strategy | M - OptEx | $6.21 | +47.5K | 458.7K | +12% | +$295.0K |
| D | 2021-10-15 | 2021-10-15 | EXEL | Lamb Peter | EVP, CSO, Scientific Strategy | S - Sale+OE | $21.92 | -47.5K | 411.2K | -10% | -$1.04M |
| 2021-10-04 | 2021-09-30 | EXEL | Senner Christopher J. | EVP, CFO | F - Tax | $20.63 | -8,573 | 415.5K | -2% | -$176.9K | |
| 2021-10-04 | 2021-09-30 | EXEL | Senner Christopher J. | EVP, CFO | A - Grant | $0.00 | +32.6K | 424.1K | +8% | $0 | |
| 2021-10-04 | 2021-09-30 | EXEL | Haley Patrick J. | EVP, Commercial | A - Grant | $0.00 | +28.9K | 309.9K | +10% | $0 | |
| 2021-10-04 | 2021-09-30 | EXEL | Haley Patrick J. | EVP, Commercial | F - Tax | $20.63 | -5,416 | 304.5K | -2% | -$111.7K | |
| 2021-10-04 | 2021-09-30 | EXEL | Hessekiel Jeffrey | EVP, GC | A - Grant | $0.00 | +28.9K | 658.4K | +5% | $0 | |
| 2021-10-04 | 2021-09-30 | EXEL | Hessekiel Jeffrey | EVP, GC | F - Tax | $20.63 | -7,593 | 650.8K | -1% | -$156.6K | |
| 2021-10-04 | 2021-09-30 | EXEL | Lamb Peter | EVP, CSO, Scientific Strategy | A - Grant | $0.00 | +28.9K | 418.4K | +7% | $0 | |
| 2021-10-04 | 2021-09-30 | EXEL | Lamb Peter | EVP, CSO, Scientific Strategy | F - Tax | $20.63 | -7,177 | 411.2K | -2% | -$148.1K | |
| D | 2021-09-23 | 2021-09-21 | EXEL | Senner Christopher J. | EVP, CFO | F - Tax | $20.33 | -55.1K | 391.5K | -12% | -$1.12M |
| D | 2021-09-23 | 2021-09-21 | EXEL | Senner Christopher J. | EVP, CFO | M - OptEx | $3.66 | +90.0K | 446.6K | +25% | +$329.4K |
| D | 2021-09-17 | 2021-09-15 | EXEL | Lamb Peter | EVP, CSO, Scientific Strategy | M - OptEx | $6.21 | +47.5K | 437.0K | +12% | +$295.0K |
| D | 2021-09-17 | 2021-09-15 | EXEL | Lamb Peter | EVP, CSO, Scientific Strategy | S - Sale+OE | $20.46 | -47.5K | 389.5K | -11% | -$971.9K |
| D | 2021-09-17 | 2021-09-16 | EXEL | Haley Patrick J. | EVP, Commercial | M - OptEx | $1.70 | +25.0K | 306.0K | +9% | +$42.5K |
| D | 2021-09-17 | 2021-09-16 | EXEL | Haley Patrick J. | EVP, Commercial | S - Sale+OE | $20.36 | -25.0K | 281.0K | -8% | -$509.0K |
| D | 2021-08-18 | 2021-08-16 | EXEL | Lamb Peter | EVP, CSO, Scientific Strategy | S - Sale+OE | $18.44 | -55.0K | 389.5K | -12% | -$1.01M |
| D | 2021-08-18 | 2021-08-16 | EXEL | Lamb Peter | EVP, CSO, Scientific Strategy | M - OptEx | $1.90 | +55.0K | 444.5K | +14% | +$104.5K |
| D | 2021-07-28 | 2021-07-26 | EXEL | Schwab Gisela | Pres, CMO, Prod Dev, Med Aff | M - OptEx | $4.20 | +40.0K | 689.1K | +6% | +$168.0K |
| D | 2021-07-23 | 2021-07-21 | EXEL | Schwab Gisela | Pres, CMO, Prod Dev, Med Aff | M - OptEx | $4.20 | +35.0K | 649.1K | +6% | +$147.0K |
| D | 2021-07-16 | 2021-07-15 | EXEL | Lamb Peter | EVP, CSO, Scientific Strategy | S - Sale+OE | $17.47 | -60.0K | 389.5K | -13% | -$1.05M |
| D | 2021-07-16 | 2021-07-15 | EXEL | Lamb Peter | EVP, CSO, Scientific Strategy | M - OptEx | $1.90 | +60.0K | 449.5K | +15% | +$114.0K |
| DM | 2021-07-08 | 2021-07-06 | EXEL | COHEN CHARLES | Dir | M - OptEx | $4.71 | +80.0K | 221.4K | +57% | +$377.2K |
Purchase Sale Sale after option exercise All abbreviations